Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Celator Pharmaceuticals Inc (CPXX) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/13/2018 CT ORDER Form CT ORDER - Confidential treatment order:
02/15/2017 SC 13G/A Thomas, McNerney & Partners II L.P. reports a 0% stake in Celator Pharmaceuticals, Inc.
02/14/2017 SC 13G/A QUAKER BIO VENTURES LP reports a 0% stake in Celator Pharmaceuticals, Inc.
01/30/2017 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals [Amend]
08/02/2016 EFFECT Form EFFECT - Notice of Effectiveness
07/27/2016 POS AM Form POS AM - Post-Effective amendments for registration statement
07/22/2016 15-12B Form 15-12B - Securities registration termination [Section 12(b)]
07/15/2016 SC 13D/A CAXTON CORP reports a 0% stake in Celator Pharmaceuticals, Inc.
07/12/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
07/12/2016 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
07/12/2016 POS AM Form POS AM - Post-Effective amendments for registration statement
07/12/2016 8-K Quarterly results
07/12/2016 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
07/12/2016 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party [Amend]
07/06/2016 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party [Amend]
06/29/2016 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party [Amend]
06/27/2016 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party [Amend]
06/22/2016 SC 13D/A CAXTON CORP reports a 7.2% stake in Celator Pharmaceuticals, Inc.
06/15/2016 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans
06/14/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Celator Pharmaceuticals ® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia"
06/10/2016 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements
06/10/2016 SC TO-T Form SC TO-T - Tender offer statement by Third Party
06/06/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Celator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ Significantly Improved Overall Survival — First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a pivotal Phase 3 trial in high-risk AML— — Data presented at the American Society of Clinical Oncology"
06/01/2016 SC 13D/A CAXTON CORP reports a 7.4% stake in Celator Pharmaceuticals, Inc.
06/01/2016 SC14D9C Form SC14D9C - Written communication relating to third party tender offer
06/01/2016 SC14D9C Form SC14D9C - Written communication relating to third party tender offer
06/01/2016 SC14D9C Form SC14D9C - Written communication relating to third party tender offer
05/31/2016 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
05/31/2016 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/31/2016 8-K Form 8-K - Current report
05/31/2016 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party
05/10/2016 10-Q Quarterly Report for the period ended March 31, 2016
04/28/2016 DEF 14A Form DEF 14A - Other definitive proxy statements
04/27/2016 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy